Cabozantinib (XL-184)

cabozantinib · Exelixis, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cabozantinib (XL-184), covering 2017-02-03 to 2017-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma [Phase 2]